TOKYO-METROPOLITAN
6.7.2021 16:06:06 CEST | Business Wire | Press release
With the Olympic Games just around the corner, Tokyo Governor Koike Yuriko sent a video message to the world's media inviting them to the Tokyo Media Center (TMC) provided by the Tokyo Metropolitan Government. TMC offers services not only for members of the press coming to Tokyo but also those working from their home countries, a great opportunity to cover the Games and the City online no matter how far away. Registration is required for full use of member services. Do not miss the opportunity to receive regular full online updates about what’s happening in Tokyo during the Games!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005509/en/
Find the video invitation form Koike Yuriko, the Governor of Tokyo at https://tokyo.mediacenter.jp/about/
Register Now!
| 1) | Access TMC’s registration page at https://tokyo.mediacenter.jp/?modal=register |
|
| 2) | Submit your name and email for Account Registration. |
|
| 3) | Register your ID and proof of employment with the Accreditation Application at https://tokyo.mediacenter.jp/login/ |
Benefits of TMC Online Service
1) |
TMC Web will be your home for various information during the Games, including photos, videos, data regarding Tokyo and more. |
|
2) |
TMC Newsletters will update you twice a day with what’s happening in Tokyo during the Games. |
|
3) |
TMC Briefings will live-stream daily briefings from the Tokyo Metropolitan Government. You can cast questions to the officials. They are scheduled from 12:30 pm to 1:00 pm, Japan Standard Time (JST), from July 23 to August 8 and from August 24 to September 5, 2021. |
|
4) |
TMC Talks will video-stream daily live presentations and recorded messages by Governor Koike and/or global leaders from various fields such as sports, culture and urban development. The main theme will be the future of Tokyo. You can cast questions to speakers via online tools. More details about TMC Talks will be announced soon. They are scheduled from 2:00 pm to 2:40 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
|
5) |
TMC Online Concierge will answer your questions and provide consultations about Tokyo-related coverage and photography. It will be available between 8:00 am and 10:00 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
We are looking forward to serving you soon!
About the Tokyo Media Center (TMC)
The Tokyo Media Center (TMC) has been set up by the Tokyo Metropolitan Government to serve as a media coverage base for domestic and international media during the Olympic and Paralympic Games Tokyo 2020. TMC provides information related to the host city Tokyo as well as the Tokyo 2020 Games. It is totally separate from the Main Press Centre (MPC) and International Broadcast Centre (IBC), which are operated by the Tokyo 2020 Organising Committee.
Website
URL: https://tokyo.mediacenter.jp/
Facilities
Date and Time of Opening: |
|
Wednesday, July 21, 2021 to Monday, August 9, 8:00 am to 10:00 pm, JST |
|
Monday, August 23, 2021 to Sunday, September 5, 8:00 am to 10:00 pm, JST |
|
* A pre-opening is scheduled on Monday, July 19 and Tuesday, July 20. The details will be announced separately. |
|
Access: |
Tokyo Sports Square, 2nd and 3rd Floor (address: Marunouchi 3-8-3, Chiyoda-ku, Tokyo) |
1 minute walk from JR Yurakucho Station and Tokyo Metro Yurakucho Station |
|
Services: |
Workspace and lounge |
Approximately 120 seats available to create a work environment for journalists. |
|
A drink corner offering refreshments will also be provided. |
|
Information Desk |
|
Staff will respond to inquiries regarding facilities usage. Upon first entrance, guests will receive a media kit which includes complimentary Tokyo-related giveaways. |
|
Japan Showcase |
|
The Japan National Tourism Organization (JNTO) will have booths to promote Japan’s various regions and traditional culture. |
|
Japanese Liquors Booth |
|
The National Tax Agency (NTA) will have a booth to introduce Japanese liquors. |
|
Internet Connection |
|
Wi-fi available for use by registered members. |
|
* Detailed information such as COVID-19 countermeasures and how to enter the facilities will be periodically updated on the TMC website and TMC Briefings. |
|
TOKYO UPDATES
Tokyo Metropolitan Government (TMG) launched a new media platform to show the world the ever-changing face of Tokyo now and the future in May 2021. This platform features content such as articles which focus on the attractions of Tokyo and the people who live, study, and work in the city. Please be sure to check it out.
URL: https://www.tokyoupdates.metro.tokyo.lg.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom